

Cancelled before Active Statement

Statement on Discontinuation of the Study	
Sponsor	Austrian Breast & Colorectal Cancer Study Group
EudraCT No.	2010-024216-34
Study Code	ABCSCG 33
Study Title	Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy
Phase	II
Study Period	NA
No. of Sites	NA
No. of Subjects	0
Publications	NA
<p>Statement on discontinuation of the study: Study was rejected during the submission phase by the sponsor due to withdrawal of financial support by supporting pharmaceutical partners. No subjects were recruited, therefore no results/data are available.</p>	